Swiss National Bank Has $4.22 Million Stock Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

Swiss National Bank boosted its position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) by 7.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 116,800 shares of the company's stock after acquiring an additional 8,000 shares during the quarter. Swiss National Bank owned 0.16% of SpringWorks Therapeutics worth $4,220,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in SWTX. AlphaQuest LLC increased its holdings in SpringWorks Therapeutics by 70.2% in the fourth quarter. AlphaQuest LLC now owns 1,004 shares of the company's stock valued at $36,000 after buying an additional 414 shares during the last quarter. Raymond James Financial Inc. bought a new position in SpringWorks Therapeutics during the fourth quarter worth $10,527,000. Arizona State Retirement System boosted its holdings in SpringWorks Therapeutics by 7.5% in the fourth quarter. Arizona State Retirement System now owns 17,206 shares of the company's stock worth $622,000 after purchasing an additional 1,206 shares during the period. M&T Bank Corp increased its stake in SpringWorks Therapeutics by 16.0% during the fourth quarter. M&T Bank Corp now owns 20,155 shares of the company's stock valued at $728,000 after purchasing an additional 2,774 shares during the last quarter. Finally, Assetmark Inc. lifted its position in shares of SpringWorks Therapeutics by 4.8% in the 4th quarter. Assetmark Inc. now owns 48,216 shares of the company's stock worth $1,742,000 after buying an additional 2,196 shares during the last quarter.

Remove Ads

SpringWorks Therapeutics Price Performance

Shares of SWTX traded down $0.08 on Friday, reaching $47.41. 1,332,631 shares of the stock traded hands, compared to its average volume of 1,297,676. The firm has a market cap of $3.55 billion, a price-to-earnings ratio of -13.62 and a beta of 0.76. SpringWorks Therapeutics, Inc. has a 12 month low of $28.21 and a 12 month high of $62.00. The stock's 50-day moving average price is $47.98 and its 200-day moving average price is $39.75.

SpringWorks Therapeutics (NASDAQ:SWTX - Get Free Report) last issued its earnings results on Thursday, February 20th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.66) by ($0.38). The company had revenue of $61.55 million during the quarter, compared to analyst estimates of $60.53 million. SpringWorks Therapeutics had a negative return on equity of 46.74% and a negative net margin of 134.73%. As a group, equities research analysts forecast that SpringWorks Therapeutics, Inc. will post -2.05 earnings per share for the current fiscal year.

Analysts Set New Price Targets

SWTX has been the topic of several analyst reports. Guggenheim dropped their price target on shares of SpringWorks Therapeutics from $80.00 to $78.00 and set a "buy" rating on the stock in a research note on Wednesday, January 8th. Evercore ISI increased their target price on shares of SpringWorks Therapeutics from $60.00 to $65.00 and gave the company an "outperform" rating in a research report on Wednesday, February 12th. Wedbush reaffirmed an "outperform" rating and issued a $81.00 price target on shares of SpringWorks Therapeutics in a research note on Thursday, February 20th. Finally, HC Wainwright reiterated a "buy" rating and set a $74.00 price objective on shares of SpringWorks Therapeutics in a research note on Friday, February 21st. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of "Buy" and an average price target of $73.20.

Insiders Place Their Bets

In other SpringWorks Therapeutics news, insider Bhavesh Ashar sold 1,016 shares of the company's stock in a transaction dated Thursday, February 20th. The shares were sold at an average price of $61.19, for a total transaction of $62,169.04. Following the transaction, the insider now directly owns 62,053 shares in the company, valued at approximately $3,797,023.07. This represents a 1.61 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Saqib Islam sold 29,328 shares of the firm's stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $60.30, for a total transaction of $1,768,478.40. Following the completion of the transaction, the chief executive officer now directly owns 1,034,625 shares in the company, valued at approximately $62,387,887.50. The trade was a 2.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 440,766 shares of company stock valued at $24,402,956 in the last 90 days. 7.61% of the stock is currently owned by insiders.

SpringWorks Therapeutics Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.